41639-83-2
41639-83-2 structure
- Name: LatanoprostAcid
- Chemical Name: latanoprost free acid
- CAS Number: 41639-83-2
- Molecular Formula: C23H34O5
- Molecular Weight: 390.513
- Catalog: Signaling Pathways GPCR/G Protein Prostaglandin Receptor
- Create Date: 2018-07-11 15:40:39
- Modify Date: 2025-08-21 20:05:57
-
Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor[1]. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes[2].
| Name | latanoprost free acid |
|---|---|
| Synonyms |
(5Z)-7-{(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoic acid
Latanoprost acid latanoprost free acid 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, (5Z)- LatanoprostAcid (5Z)-7-{(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}-5-heptenoic acid |
| Description | Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor[1]. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes[2]. |
|---|---|
| Related Catalog | |
| Target |
FP |
| In Vitro | Latanoprost acid (10-20 μM;24 hours) reduces he protein expressions of c-fos and NFATc1[1]. Latanoprost acid (10μM with 50ng/ml RANKL) significantly inhibits ERK, p38, AKT and JNK[1]. Latanoprost acid (10 μM, 20 μM) significantly inhibits the mature osteoclast formation[1]. Western Blot Analysis[1] Cell Line: Bone marrow-derived macrophages cells (BMMs) Concentration: 10 μM, 20 μM Incubation Time: 24 hours Result: Reduced he protein expressions of c-fos and NFATc1. |
| In Vivo | Latanoprost acid (i.p.; 20 mg/kg; once a day for 7 days) notably prevents LPS-induced bone destruction at a dose of 20mg/kg[1]. Animal Model: 8-week-old C57BL/6J mice[1] Dosage: 20 mg/kg Administration: Intraperitoneally injected; once a day for 7 days Result: Notably prevented LPS-induced bone destruction at a dose of 20mg/kg. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 609.1±50.0 °C at 760 mmHg |
| Molecular Formula | C23H34O5 |
| Molecular Weight | 390.513 |
| Flash Point | 336.2±26.6 °C |
| Exact Mass | 390.240631 |
| PSA | 97.99000 |
| LogP | 2.22 |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.564 |
| Storage condition | -20°C |
| Personal Protective Equipment | Eyeshields;Gloves |
|---|---|
| RIDADR | NONH for all modes of transport |
| Precursor 7 | |
|---|---|
| DownStream 2 | |
![[1,1'-Biphenyl]-4-carboxylic acid (3aR,4R,5R,6aS)-hexahydro-2-oxo-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-5-yl ester structure](https://image.chemsrc.com/caspic/473/41639-72-9.png)
![(1S,5R,6R,7R)-6-[(3S)-3-hydroxy-5-phenyl-1-pentenyl]-7-[(4-phenylbenzoyl)oxy]-2-oxabicyclo[3.3.0]octan-3-one structure](https://image.chemsrc.com/caspic/470/41639-23-0.png)
